# SERETIDE 100/50 bd (Twice Daily) Versus FLIXOTIDE 100 bd As Initial Maintenance Therapy In Moderate Asthma In Adults

> **NCT00461500** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 81 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Salmeterol xinafoate/fluticasone propionate combination
- **DRUG:** Fluticasone propionate

## Key facts

- **NCT ID:** NCT00461500
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2017-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00461500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00461500, "SERETIDE 100/50 bd (Twice Daily) Versus FLIXOTIDE 100 bd As Initial Maintenance Therapy In Moderate Asthma In Adults". Retrieved via MORVS 2026-10-24 from https://api.morvs.ai/clinical/NCT00461500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*